Critical review of GABA-ergic drugs in the treatment of schizophrenia

Adel A. Wassef, Sharon G. Dott, Ann Harris, Alston Brown, Michael O'Boyle, Walter Meyer, Robert M. Rose

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

GABA-ergic medications may have a potential role in the treatment of schizophrenia. Laboratory evidence has generally supported the ability of γ- aminobutyric acid (GABA) to reduce dopaminergic activity and has suggested that GABA may be effective in combating hypofrontality by acting on mesoprefrontocortical tracts in patients resistant to treatment with antipsychotic drugs. Although the results of clinical trials of several GABA- ergic compounds have been inconclusive because of methodologic limitations and drug toxicity, benzodiazepines and valproate seem to be associated with favorable treatment outcomes, especially when combined with typical antipsychotic agents. This study concludes that further investigation of the use of GABA in schizophrenia is likely to improve the understanding of the psychopathology of this illness and to expand our treatment alternatives. Also provided are suggestions to enhance the design of future studies, improve the potential for favorable treatment outcomes, and assist in predicting patients' responses to GABA-ergic medications.

Original languageEnglish (US)
Pages (from-to)222-232
Number of pages11
JournalJournal of Clinical Psychopharmacology
Volume19
Issue number3
DOIs
StatePublished - Jun 1999

Fingerprint

Aminobutyrates
Aptitude
Schizophrenia
Pharmaceutical Preparations
Antipsychotic Agents
Therapeutics
Valproic Acid
Drug-Related Side Effects and Adverse Reactions
Psychopathology
Benzodiazepines
Clinical Trials

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Wassef, A. A., Dott, S. G., Harris, A., Brown, A., O'Boyle, M., Meyer, W., & Rose, R. M. (1999). Critical review of GABA-ergic drugs in the treatment of schizophrenia. Journal of Clinical Psychopharmacology, 19(3), 222-232. https://doi.org/10.1097/00004714-199906000-00004

Critical review of GABA-ergic drugs in the treatment of schizophrenia. / Wassef, Adel A.; Dott, Sharon G.; Harris, Ann; Brown, Alston; O'Boyle, Michael; Meyer, Walter; Rose, Robert M.

In: Journal of Clinical Psychopharmacology, Vol. 19, No. 3, 06.1999, p. 222-232.

Research output: Contribution to journalArticle

Wassef, AA, Dott, SG, Harris, A, Brown, A, O'Boyle, M, Meyer, W & Rose, RM 1999, 'Critical review of GABA-ergic drugs in the treatment of schizophrenia', Journal of Clinical Psychopharmacology, vol. 19, no. 3, pp. 222-232. https://doi.org/10.1097/00004714-199906000-00004
Wassef, Adel A. ; Dott, Sharon G. ; Harris, Ann ; Brown, Alston ; O'Boyle, Michael ; Meyer, Walter ; Rose, Robert M. / Critical review of GABA-ergic drugs in the treatment of schizophrenia. In: Journal of Clinical Psychopharmacology. 1999 ; Vol. 19, No. 3. pp. 222-232.
@article{3400266d38cd4c508dcb62b06586f0e0,
title = "Critical review of GABA-ergic drugs in the treatment of schizophrenia",
abstract = "GABA-ergic medications may have a potential role in the treatment of schizophrenia. Laboratory evidence has generally supported the ability of γ- aminobutyric acid (GABA) to reduce dopaminergic activity and has suggested that GABA may be effective in combating hypofrontality by acting on mesoprefrontocortical tracts in patients resistant to treatment with antipsychotic drugs. Although the results of clinical trials of several GABA- ergic compounds have been inconclusive because of methodologic limitations and drug toxicity, benzodiazepines and valproate seem to be associated with favorable treatment outcomes, especially when combined with typical antipsychotic agents. This study concludes that further investigation of the use of GABA in schizophrenia is likely to improve the understanding of the psychopathology of this illness and to expand our treatment alternatives. Also provided are suggestions to enhance the design of future studies, improve the potential for favorable treatment outcomes, and assist in predicting patients' responses to GABA-ergic medications.",
author = "Wassef, {Adel A.} and Dott, {Sharon G.} and Ann Harris and Alston Brown and Michael O'Boyle and Walter Meyer and Rose, {Robert M.}",
year = "1999",
month = "6",
doi = "10.1097/00004714-199906000-00004",
language = "English (US)",
volume = "19",
pages = "222--232",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Critical review of GABA-ergic drugs in the treatment of schizophrenia

AU - Wassef, Adel A.

AU - Dott, Sharon G.

AU - Harris, Ann

AU - Brown, Alston

AU - O'Boyle, Michael

AU - Meyer, Walter

AU - Rose, Robert M.

PY - 1999/6

Y1 - 1999/6

N2 - GABA-ergic medications may have a potential role in the treatment of schizophrenia. Laboratory evidence has generally supported the ability of γ- aminobutyric acid (GABA) to reduce dopaminergic activity and has suggested that GABA may be effective in combating hypofrontality by acting on mesoprefrontocortical tracts in patients resistant to treatment with antipsychotic drugs. Although the results of clinical trials of several GABA- ergic compounds have been inconclusive because of methodologic limitations and drug toxicity, benzodiazepines and valproate seem to be associated with favorable treatment outcomes, especially when combined with typical antipsychotic agents. This study concludes that further investigation of the use of GABA in schizophrenia is likely to improve the understanding of the psychopathology of this illness and to expand our treatment alternatives. Also provided are suggestions to enhance the design of future studies, improve the potential for favorable treatment outcomes, and assist in predicting patients' responses to GABA-ergic medications.

AB - GABA-ergic medications may have a potential role in the treatment of schizophrenia. Laboratory evidence has generally supported the ability of γ- aminobutyric acid (GABA) to reduce dopaminergic activity and has suggested that GABA may be effective in combating hypofrontality by acting on mesoprefrontocortical tracts in patients resistant to treatment with antipsychotic drugs. Although the results of clinical trials of several GABA- ergic compounds have been inconclusive because of methodologic limitations and drug toxicity, benzodiazepines and valproate seem to be associated with favorable treatment outcomes, especially when combined with typical antipsychotic agents. This study concludes that further investigation of the use of GABA in schizophrenia is likely to improve the understanding of the psychopathology of this illness and to expand our treatment alternatives. Also provided are suggestions to enhance the design of future studies, improve the potential for favorable treatment outcomes, and assist in predicting patients' responses to GABA-ergic medications.

UR - http://www.scopus.com/inward/record.url?scp=0032956649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032956649&partnerID=8YFLogxK

U2 - 10.1097/00004714-199906000-00004

DO - 10.1097/00004714-199906000-00004

M3 - Article

VL - 19

SP - 222

EP - 232

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 3

ER -